Enrollment Complete in Lipogems ARISE I Study

Lipogems ARISE I U.S. FDA IDE study

Lipogems completed enrollment in the ARISE I U.S. FDA Investigational Device Exemption study, which aims to examine MicroFat versus corticosteriod injection for the treatment of knee osteoarthritis (OA). Efficacy and safety results from ARISE 1 are expected to be announced in 2025.

This double-blinded randomized controlled trial was...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us